| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | DGSX ELISA Kit; Glypican proteoglycan 3 ELISA Kit; Glypican-3 [Precursor] ELISA Kit; Gpc3 ELISA Kit; GPC3_HUMAN ELISA Kit; GTR2 2 ELISA Kit; GTR2-2 ELISA Kit; Heparan sulphate proteoglycan ELISA Kit; Intestinal protein OCI 5 ELISA Kit; Intestinal protein OCI-5 ELISA Kit; MXR7 ELISA Kit; OCI 5 ELISA Kit; OCI-5 ELISA Kit; OCI5 ELISA Kit; SDYS ELISA Kit; Secreted glypican-3 ELISA Kit; SGB ELISA Kit; SGBS ELISA Kit; SGBS1 ELISA Kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, urine, cell culture supernates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
Glypican-3 (GPC3) is a biological molecule commonly studied in signal transduction research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.
UniProt: P51654
Biological context
Researchers often monitor Glypican-3 in serum, urine, and cell culture supernates to better understand themes such as mechanistic biology studies, biomarker-focused profiling, and disease-model research. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in Glypican-3 may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, complementary pathway markers and controls appropriate to the biological model) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, Glypican-3 may also appear under names such as DGSX and Glypican proteoglycan 3. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Glypican-3 participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Serum Level of Glypican-3 in Patients with Hepatocellular Carcinoma and Advanced Chronic Liver Disease: A Pilot Study
I Ivanova, S Banova-Chakyrova, P Boykova-Vylcheva,Livers,2025
Microvascular perfusion, perfused boundary region and glycocalyx shedding in patients with autosomal dominant polycystic kidney disease: results from the GlycoScore III study
A Fuchs,Clinical Kidney Journal,2022
GPC3 in the Exosomes from Hepatocellular Carcinoma HepG2 Cells
C Pu,Researchsquare,2021
Is Glypican-3 useful Diagnostic Marker that Distinguishes Hepatocellular Carcinoma from Liver Cirrhosis?
SA Omar,Afro-Egyptian Journal of Infectious and Endemic Diseases,2020
Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Zhou F.et al,Med Res Rev,2017
Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma
Yao M et al,Hepatobiliary Pancreat Dis Int.,2013
Golgi protein 73, not Glypican-3,May be a tumorMarker complementary to A-Fetoprotein for hepatocellular carcinoma diagnosis
Wang Y et al,J Gastroenterol Hepatol,2013
Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients
Ozkan H et al,J Clin Lab Anal,2011